Hydrochloric Acid

Hydrochloric Acid

SCHEMBL131902

Cl.Cn1c2c(c3ccc(-n4ccc(OCc5ccc(C(F)(F)F)nc5)cc4=O)cc31)CN1CCCC1C2

nearest known ligand 0.99

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 20/20 0.99

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173055 0.99 MCHR1 (1.00) MCHR1
Hydrochloric Acid SCHEMBL130887 0.98 MCHR1 (0.99) MCHR1
SCHEMBL173069 0.97 MCHR1 (1.00) MCHR1
Hydrochloric Acid SCHEMBL133328 0.90 MCHR1 (0.98) MCHR1
SCHEMBL94171 0.89 MCHR1 (1.00) MCHR1
Hydrochloric Acid SCHEMBL130889 0.88 MCHR1 (0.98) MCHR1
SCHEMBL94378 0.87 MCHR1 (1.00) MCHR1
Hydrochloric Acid SCHEMBL132302 0.86 MCHR1 (0.98) MCHR1
Hydrochloric Acid SCHEMBL132307 0.86 MCHR1 (0.98) MCHR1
SCHEMBL173059 0.85 MCHR1 (1.00) MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160260519-A1 SUSTAINABLE POLY(VINYL HALIDE) MIXTURES FOR THIN-FILM APPLICATIONS POLYONE CORPORATION (US) 2016-09-08 US disclosed
EP-2310451-B1 HIGH FLOW POLYVINYL HALIDE COMPOUND AND METHODS OF MAKING AND USING SAME POLYONE CORP (US) 2015-05-06 EP disclosed
WO-2015047999-A1 SUSTAINABLE POLY(VINYL HALIDE) MIXTURES FOR THIN-FILM APPLICATIONS POLYONE CORPORATION (US) 2015-04-02 WO disclosed
US-8575247-B2 High flow polyvinyl halide compound and methods of making and using same POLYONE CORPORATION (US) 2013-11-05 US disclosed
US-8273283-B2 Method of making molded articles POLYONE CORPORATION (US) 2012-09-25 US disclosed
US-8273283-B2 Method of making molded articles POLYONE CORPORATION (US) 2012-09-25 US disclosed
US-20120058940-A9 AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2012-03-08 US disclosed
EP-1966303-B1 Polymer skin made from an uncrosslinked alloy POLYONE CORP (US) 2012-03-07 EP disclosed
US-20110177293-A1 METHOD OF MAKING MOLDED ARTICLES POLYONE CORPORATION (US) 2011-07-21 US disclosed
US-20110177293-A1 METHOD OF MAKING MOLDED ARTICLES POLYONE CORPORATION (US) 2011-07-21 US disclosed
EP-2310451-A2 HIGH FLOW POLYVINYL HALIDE COMPOUND AND METHODS OF MAKING AND USING SAME PolyOne Corporation (US) 2011-04-20 EP disclosed
US-20110003738-A1 AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-06 US disclosed
US-20100112288-A1 METHOD OF MAKING MOLDED ARTICLES POLYONE CORPORATION (US) 2010-05-06 US disclosed
US-20100112288-A1 METHOD OF MAKING MOLDED ARTICLES POLYONE CORPORATION (US) 2010-05-06 US disclosed
US-20090239984-A1 POLYVINYL HALIDE-UNCROSSLINKED ELASTOMER ALLOY POLYONE CORPORATION (US) 2009-09-24 US disclosed
WO-2008121140-A1 METHOD OF MAKING MOLDED ARTICLES POLYONE CORPORATION (US) 2008-10-09 WO disclosed
EP-0617057-B1 Pseudo-living radical polymerization GEON CO (US) 2000-07-12 EP disclosed
EP-0974604-A2 Pseudo-living radical polymerization of vinyl halide chain transfer agent and method of making agent The Geon Company (US) 2000-01-26 EP disclosed
US-5455319-A Also adding free radical generating initiator; low molecular weight polymer product, polydispersity THE GEON COMPANY (US) 1995-10-03 US disclosed
EP-0617057-A1 Pseudo-living radical polymerization The Geon Company (US) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003738-A1 AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF MCHR1, MCHR2, TAAR1 MCHR1 1/4885
US-20120058940-A9 AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF MCHR1, MCHR2, TAAR1 MCHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.